Welcome to the Hope Bio Blog

Written by Jan Shultis Billions of stem cells manufactured through proprietary technology by Houston-area biotechnology company Hope Biosciences are soon to be pressed into the fight against Alzheimer’s Disease (AD). The U.S. Food and Drug Administration (FDA) has authorized an open label Phase Ib/IIa clinical trial to evaluate whether Hope Biosciences autologous, adipose-derived mesenchymal stem cells (HB-adMSCs) reduce inflammation in the brain, improve brain activity, an

Partnering with Altoida, Inc. to Leverage Predictive Digital Biomarkers for Detection of Mild Cognitive Impairment due to Alzheimer’s Disease Hope Biosciences, a clinical stage biotechnology company focused on developing cell-based therapeutics for acute and chronic disease, today announced that FDA has approved a Phase I/II clinical trial evaluating safety and efficacy of Hope Biosciences’ autologous, adipose-derived mesenchymal stem cells (HB-adMSCs) for Alzheimer’s Disease